tbuckley/cabot-search huggingface dataset:
Worse prognosis of <i>KRAS</i> C.35 G &gt; A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).
Authors: Gemma Bruera, Katia Cannita, Daniela Di Giacomo, Aude Lamy, Giancarlo Troncone, Antonella Dal Mas, Gino Coletti, Thierry Frébourg, Jean-Christophe Sabourin, Mario Tosi, Corrado Ficorella, Enrico Ricevuto
Journal: Journal of Clinical Oncology (2012)

521 Background: Bevacizumab (BEV) addition to doublet chemotherapy significantly increases efficacy without differentially affecting prognosis in KRAS wild-type (wt) and mutant (m) MCRC. Present study evaluates clinical outcome of BEV added to triplet chemotherapy, FIr-B/FOx (Bruera G et al, BMC Cancer 2010, 10:567), according to KRAS genotype. Methods: MCRC patients (pts) were treated with first line FIr-B/FOx regimen including BEV (5 mg/kg, days 1,15) and triplet chemotherapy, weekly alternating irinotecan (160 mg/m 2 days 1,15) or oxaliplatin (80 mg/m 2 , days 8, 22) associated to fluorouracil (900 mg/m 2 , days 1-2, 8-9, 15-16, 22-23); every 4 weeks. Tumoral samples were simultaneously screened for KRAS codon 12 and 13, and BRAF c.1799 T &gt; A mutations by SNaPshot multiplex assay (Di Fiore F, Br J Cancer 2007;96(8):1166-1169) and/or direct sequencing. Activity and efficacy were evaluated and compared using log-rank test. Results: Forty-five MCRC pts were evaluated: 25 KRAS wt (56%), 20 KRAS m (44%). After 30 months median follow-up, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were, respectively: KRAS wt 88% (C.I. ± 14), 14 months, 38 months; KRAS m 80% (C.I. ± 19), 12 months, 21 months. PFS and OS were not significantly different. Among KRAS m pts, ORR, PFS and OS at 19 months median follow-up in c.35 G &gt; A (13 pts) were 69% (C.I. ± 26), 9 months, 11 months, respectively. OS of c.35 G &gt; A KRAS m was significantly worse compared to KRAS wt (p = 0.003) and to other than c.35 G &gt; A mutant pts (p = 0.022). Conclusions: First line FIr-B/FOx intensive regimen adding BEV to triplet chemotherapy can further increase activity and efficacy without significantly affecting different clinical outcome in KRAS wt and m MCRC pts. A significant interaction between the most prevalent c.35 G &gt; A KRAS mutation and worse prognosis was observed, compared to KRAS wt pts and to other than c.35 G &gt; A KRAS exon 2 mutations, depending from different biological aggressiveness and sensitivity to BEV addition to triplet chemotherapy.
Clinical, Biological Profile and Outcome of Biphenotypic Acute Leukemia: a Case Series.
Authors: Yanming Zhang, Wu Depei, Aining Sun, Huiying Qiu, Guangsheng He, Zhengming Jin, Xiaowen Tang, Miao Miao, Chengcheng Fu, Yue Han, Mingqing Zhu, Yongquan Xue, Zixing Chen, Changgeng Ruan
Journal: Blood (2010)
Robotic Intracorporeal Padua Ileal Bladder: Surgical Technique, Perioperative, Oncologic and Functional Outcomes
Authors: Giuseppe Simone, Rocco Papalia, Leonardo Misuraca, Gabriele Tuderti, Francesco Minisola, Mariaconsiglia Ferriero, Giulio Vallati, Salvatore Guaglianone, Michele Gallucci
Journal: European Urology (2016)
Prognostic value of blood levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in advanced non-small cell lung cancer (NSCLC) patients
Authors: V. Alberola, C. Camps, R. Sirera, L. Llobat, A. Blasco, M. J. Safont, J. Garde, M. Taron, J. J. Sanchez, R. Rosell
Journal: Journal of Clinical Oncology (2006)

7196 Background: VEGF and bFGF are among the most important angiogenic factors. We have explored these angiogenesis mediators in plasma and its prognostic significance in advanced NSCLC. Methods: Were enrolled 451 patients with advanced NSCLC, stages IIIB and IV and treated with cisplatin and docetaxel. Blood was collected before chemotherapy. Plasma VEGF and bFGF levels were assessed by commercial ELISA (sensitivity 5 pg/ml). In parallel plasma from 32 age and gender-matched controls was used. Results: Median age was 61 years (35–82) and 84% were males. 99% had performance status 0–1. 84% were in stage IV and 16% in stage IIIB. The histological subtypes were: 32% squamous cell carcinoma, 50% adenocarcinoma, 14% anaplastic large cell, and 4% undifferentiated. 41% of the patients received second line chemotherapy. 1% achieved complete response (CR), 36% partial response (PR), 35% had stable disease (SD) and 28% progressive disease (PD). Patient’s median plasma levels of VEGF (20 pg/ml, [6–203]) differ significantly (p = 0.04) from controls (14 pg/ml, [7–53]), but in contrast bFGF levels were not different, 14 pg/ml [5–960] vs 10 pg/ml [6–278] respectively. There were not differences in patients according to histology, site of metastasis and ECOG; however we could observe a tendency with stage for both factors: bFGF 9 pg/ml [5–24] in stage IIIB vs 15 pg/ml [6–960], p = 0.071 and VEGF 17 pg/ml [6–145] in IIIB vs 21 pg/ml [6–203] in IV, p = 0.086. It could not be observed any differences in response to therapy for both angiogenic factors; CR+PR patients presented median VEGF of 18 pg/ml [6–71] and bFGF 11 pg/ml [6–960] vs 20 pg/ml of VEGF [6–203] and 15 pg/ml of bFGF [5–395] in the SD+PD group. In the multivariate analysis we could not find that VEGF and bFGF plasma levels were predictors for time to progression (TTP) and overall survival (OS). Conclusions: VEGF but not bFGF levels in patients are significantly higher in patients than in controls. In our cohort of patients with advanced NSCLC we have not found any relationship between serum VEGF and bFGF levels with stage, histology, response, site of metastasis, TTP and OS. No significant financial relationships to disclose.
Mucinous Cystic Neoplasms of the Pancreas
Authors: Thilo Hackert, Christoph W. Michalski, Markus W. Büchler
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Obama urges Republicans to help improve health reform law
Authors: Michael McCarthy
Journal: BMJ (2016)

Barack Obama, the outgoing US president, has called on Republicans to abandon their uncompromising opposition to the Affordable Care Act and work with the next president to improve the 2010 health reform law.

Speaking on 20 October in Miami, Florida, Obama charged that Republicans had continued to seek to repeal the law—commonly called “Obamacare”—despite its successes, in part because “a Democratic president named Barack Obama passed the law.”

“Maybe now that I'm leaving office, maybe Republicans can stop with the 60-something repeal votes they’ve taken . . . and just work …
Treatment of Neurological Dysfunction in MPS VII and Batten Disease by Transplantation of Lentivirally Transduced Neuronal Stem Cells Cultured from Hematopoietic Tissue.
Authors: Brian W. Soper, Mark D. Lessard, Travis L. Alley, Jennifer L. Proctor, Anthony J. Mourino, Jane E. Barker
Journal: Blood (2005)
GW26-e2928 No Distinct Association Between COMT Val158Met Polymorphism and Blood Pressure and Serum Lipid Levels in the Oldest Olds From Guangxi Bama Area
Authors: Zhangya Bian, Yi Ding, Lin Ge, Shangling Pan, Peng Sun, Junhua Peng, Chengwu Liu
Journal: Journal of the American College of Cardiology (2015)
TGFBR1*6A germline deletion in gemcitabine (gem)/cisplatin (cis)-treated stage IV non-small cell lung cancer (NSCLC) patients (p)
Authors: M. Domine, V. Alberola, J. Muñoz-Langa, M. A. Muñoz-Quintana, M. A. Molina, N. Viñolas, J. Gonzalez-Larriba, M. López- Brea, J. J. Sanchez, M. Taron
Journal: Journal of Clinical Oncology (2007)

18171 Background: An in-frame germline deletion variant (TGFBR1*6A) in the TGFBR1 gene results in loss of three alanines within the 9-alanine (*9A) repeat in the receptor. Compared with *9A, *6A is a less effective mediator of TGFB antiproliferative signals. Methods: We examined the germline deletion TGFBR1*6A in 107 gem/cis-treated stage IV NSCLC p. DNA was extracted from peripheral lymphocytes and deletion was analyzed by length analysis of fluorescently labeled PCR products. Results: Median age, 65 (range, 32- 81); male, 100 p (93%. Performance status (PS) 0, 39 p (37%); PS 1, 52 p (48.5%); PS 2, 26 p (24.5%). Adenocarcinoma: 56 p (52%). 71.6% of p had the *9A/*9A genotype; the remaining 28.4% had the *6A/*9A genotype. Response was observed in 37 p (34.5%). Overall median survival (MS) was 8 months (m). There were no differences in response or MS between p harboring the *9A/*9A genotype and those with the *6A/*9A genotype. There was a trend towards longer MS in p with PS 0 with *9A/*9A genotype (11 m) than in thoase with *6A/*9A (3 m) (P=0.06). Conclusions: Although the findings of this study do not identify significant differences between *6A and *9A, the fact that the shorter signal sequence could confer a tumor growth advantage merits further investigation. No significant financial relationships to disclose.
IL-6-Induced C-MYC Down-Regulates the Expression of CD33 in CD33(+) Myeloma Cell Lines.
Authors: Karim Shamsasenjan, Ken-ichiro Otsuyama, Mohd S. Iqbal, Saeid Abroun, Jakia Amin, Abul Islam, Michio M. Kawano
Journal: Blood (2007)
Therapy of Acquired Aplastic Anemia (AA) with Rabbit Antithymocyte Globulin (rATG): A Retrospective Analysis by the Working Group on Non-Malignant Disorders of Hematopoiesis of the German Society of Hematology and Oncology (DGHO),
Authors: Britta Höchsmann, Christiane Neher, Ulrich Germing, Janne Vehreschild, Juliane Eggermann, Dietrich Braumann, Bernd Hertenstein, Anke Franzke, Karin Mayer, Paul La Rosée, Stefan Wilop, Karl-Heinz Pflueger, Hans-Josef Weh, Bernd Gruhn, Alfred Leipold, Mark Ringhoffer, Heinz A. Duerk, Kumar Sinah, Aristoteles Giagounidis, Hubert Schrezenmeier
Journal: Blood (2011)
GW26-e2972 Local Intracoronary Eptifibatide versus Mechanical Aspiration in Patients with Acute ST-Elevation Myocardial Infarction
Authors: Ayman Mohamed Galal Yehia ELbadawi, Mohamed A. Hamza, Salwa Suweilam, Mohamed Ismail
Journal: Journal of the American College of Cardiology (2015)
A vaccinia-based vaccine (TroVax) targeting the oncofetal antigen 5T4 administered before and after surgical resection of colorectal cancer liver metastases: Phase II trial
Authors: A. Dangoor, D. Burt, R. Harrop, N. Drury, C. Hamer, D. Andrews, D. Sherlock, P. Stern, R. Hawkins
Journal: Journal of Clinical Oncology (2006)

2574 Background: Oncofetal antigen 5T4 is expressed by most colorectal cancers. Administration of a vaccine combining a Modified Vaccinia Ankara (MVA) vector with 5T4 elicits immune responses in late-stage colorectal cancer patients. This trial seeks to investigate the immunological effects of the vaccine both in peripheral blood and locally in tumour tissue resected during potentially curative surgery for colorectal liver metastases. Some patients may have micrometastatic disease, a potential target for immunotherapy. Methods: Colorectal cancer patients selected for resection of liver metastases were eligible. Recruitment of up to 20 patients was planned. Following screening they received 2 vaccinations prior to, and 2 after, surgery. Primary endpoint was assessment of the immune response at time of surgery. Blood was taken for analysis at screening and 2 weeks after each vaccination. A tumour biopsy was obtained at surgery. T-cell responses were assessed using proliferation and gamma-interferon ELISPOT assays; ELISA used to assess serological response. Immunohistochemical analysis was used to confirm tumour antigen expression and the nature of T-cell infiltration into the liver. If 5T4-specific immune responses were demonstrated patients were offered further vaccinations at 20 and 28 weeks post surgery. Results: Of 20 patients recruited, 16 were eligible for assessment, 4 excluded, 1 due to hepatocellular carcinoma, 3 with inoperable disease. There was no grade III/IV toxicity related to vaccination. Tumour expression of 5T4 was confirmed in all cases, local T-cell infiltration consisted predominantly of CD4 cells. According to proliferation assays, 8 of 16 patients had T-cell responses at time of surgery and 12 of 16 in total to date. 14 patients have developed 5T4-specific antibody responses. At median follow up of 8.4 months 7 of 16 patients have disease recurrence. Conclusions: The MVA-5T4 vaccine (TroVax) was safe and well tolerated in all patients undergoing resection of colorectal liver metastases. 5T4 specific cellular and/or humoral immune responses were induced in the majority of patients following vaccination with TroVax. [Table: see text]
Cost-Effectiveness of Antifungal Strategies in High-Risk Neutropenic Patients
Authors: Michael Schwarzinger, Sylvain Baillot, Celine Beauchamp, Sebastien Maury, C. écile Pautas, Anne Vekhoff, Hassan Farhat, Felipe Suarez, Francois Hemery, Mathieu Kuentz, Catherine Cordonnier
Journal: Blood (2008)
ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma.
Authors: Gail A. Rock, David Anderson, Barrett Benny, David Barth, William Clark, Ronan Foley, David Sutton, Pierre Leblond
Journal: Blood (2007)
Phase 2 study of PS-341 (bortezomib) in the treatment of metastatic malignant melanoma (MMM)
Authors: S. M. Geyer, S. M. Markovic, T. R. Fitch, M. R. Albertini, W. J. Maples, P. M. Fracasso, C. Erlichman
Journal: Journal of Clinical Oncology (2004)

7526 Background: PS-341 is an agent that appeared to have anti-melanoma properties in pre-clinical studies both in vitro and in vivo, providing a rationale for studying this agent in MMM. Methods: Eligible patients (pts) had measurable disease, adequate hematologic, renal, and hepatic function, and were chemonaive. PS-341 was administered at 1.5 mg/m2 IV bolus twice weekly for 2 weeks q 3 weeks. Results: 27 pts were accrued, with a median age of 56 years (range: 32–77). 33% were female, 70% had an ECOG PS of 0, 30% had a PS of 1. Two pts had no prior treatment, 64% had prior surgery, and 56% had prior immunotherapy. 26 pts were evaluable for toxicity, of which 10 pts (42%) had grade 3 toxicities (at least possibly related to treatment), including: sensory neuropathy (3), thrombocytopenia (3), constipation (2), fatigue (1), ileus (1), abdominal pain (1), infection w/o neutropenia (1), and platelet transfusion (1). No grade 5 events were reported. No pts are currently receiving treatment. 74% of pts discontinued treatment due to disease progression, 15% due to adverse reactions, and 11% for refusal or other reasons. The median duration of treatment was 1.5 months. The study initially required a maximum of 45 pts, but the study was closed after the interim analysis showed insufficient activity. There were no CRs or PRs, and only 6 pts (22%) achieved stable disease for at least one cycle. Four pts were stable for 4 cycles of treatment, and all 4 of these pts went off study due to adverse reactions. To date, 56% of pts are alive, 96% have progressed, and the median time to progression was 1.5 months. Conclusion: PS-341 is ineffective and toxic in metastatic melanoma pts at the dose and schedule used in this trial. Supported by N01-CM-17104. No significant financial relationships to disclose.
Prevention Strategies for Contrast-Induced Nephropathy
Authors: James Cain, Jamie Goldstone
Journal: Annals of Internal Medicine (2016)

Letters18 October 2016Prevention Strategies for Contrast-Induced NephropathyJames Cain, MD and Jamie Goldstone, MPHJames Cain, MDFrom Virginia Tech Carilion School of Medicine and Jefferson College of Health Sciences, Roanoke, Virginia.Search for more papers by this author and Jamie Goldstone, MPHFrom Virginia Tech Carilion School of Medicine and Jefferson College of Health Sciences, Roanoke, Virginia.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0279 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Subramaniam and colleagues' meta-analysis of contrast-induced nephropathy (1) and any analysis of N-acetylcysteine (NAC) and creatinine levels may be erroneous because of inaccurate creatinine measurements. Siemens Healthcare Diagnostics issued an Urgent Medical Device Correction on 17 March 2016 about an interfering substance affecting creatinine measurements using the Trinder and Trinder-like reaction assays. This reaction results in falsely low creatinine levels in the presence of NAC. Roche Diagnostics issued a similar warning in May 2015, and Genzen and associates (2) described this interference in October 2015.The patients included in Subramaniam and colleagues' meta-analysis received NAC in an ...References1. Subramaniam RM, Suarez-Cuervo C, Wilson RF, Turban S, Zhang A, Sherrod C, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:406-16. [PMID: 26830221]. doi:10.7326/M15-1456 LinkGoogle Scholar2. Genzen JR, Hunsaker JJ, Nelson LS, Faine BA, Krasowski MD. N-acetylcysteine interference of Trinder-based assays. Clin Biochem. 2016;49:100-4. [PMID: 26500003] doi:10.1016/j.clinbiochem.2015.10.005 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Virginia Tech Carilion School of Medicine and Jefferson College of Health Sciences, Roanoke, Virginia.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0279. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffectiveness of Prevention Strategies for Contrast-Induced Nephropathy Rathan M. Subramaniam , Catalina Suarez-Cuervo , Renee F. Wilson , Sharon Turban , Allen Zhang , Cheryl Sherrod , Jonathan Aboagye , John Eng , Michael J. Choi , Susan Hutfless , and Eric B. Bass Prevention Strategies for Contrast-Induced Nephropathy Eric B. Bass and Rathan M. Subramaniam Metrics 18 October 2016Volume 165, Issue 8Page: 600-601KeywordsConflicts of interestCreatinineDiagnostic techniquesDisclosureHealth care ePublished: 18 October 2016 Issue Published: 18 October 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
GW26-e3983 Ca2+/calmodulin-dependent protein kinase modulation of torsade de pointes arrhythmogenesis and identification of targeted sites of antiarrhythmic therapy in human Timothy Syndrome arising from a new CACNA1C mutation
Authors: Jieyun Bai, Kuanquan Wang, Henggui Zhang
Journal: Journal of the American College of Cardiology (2015)
Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).
Authors: Alessandra Ferrajoli, Xavier C. Badoux, Susan O'Brien, William G. Wierda, Stefan Faderl, Zeev Estrov, Manolo Pasia, Bang-Ning Lee, James M. Reuben, Hagop Kantarjian, Michael Keating
Journal: Blood (2009)
Secondary Lymphoid Tissues Are Not Required for the Induction of GVHD Following Allogeneic BMT: A Shifting Paradigm for T Cell Allo-Activation.
Authors: Ines A. Silva, Krystyna Olkiewicz, Jacquelyn M. Fisher, Meghana N. Chaudhary, Kevin Vannella Vannella, Daphne T. Deurloo, Sung W. Choi, Chen Liu, Kenneth R. Cooke
Journal: Blood (2006)
A bibliometric analysis of exertional heat stroke research in Web of Science
Authors: Zhi Mao, Chao Liu, Shuo Chen, Zheng-Guo Zhu, Hong-Jun Kang, Fei-Hu Zhou
Journal: Military Medical Research (2016)

Exertional heat stroke is a fatal condition and remains a health problem. This paper evaluates the publication trend regarding exertional heat stroke research between 1996 and 2015 using a bibliometric method. Articles regarding exertional heat stroke research published between 1996 and December 2015 were searched for in the SCI-EXPANDED database of Web of Science. The search results were analyzed with regard to publication year; publication quantity regarding countries/regions, and authors; citation frequency; and journal distribution. CiteSpace (v3.6) was used for a document co-citation visualization analysis. In total, 289 publications on heat stroke were located. After selection, 209 original articles conducted across 28 countries/regions and published in 83 journals were included in the analysis. The USA, Isreal, and France were the most common locations for exertional heat stroke studies. The CiteSpace visualization cluster analysis showed that exertional heat stroke-related mortality and protective measures were constant concerns of research. Research related to exertional heat stroke has been continuous concerned. USA is still the leading country in this field.
Survival benefit of gefitinib treated non-small-cell lung cancer patients with exon 19 deletion mutations in epidermal growth factor receptor (EGFR), detected by a new sensitive PCR-based method
Authors: E. Nakajima, M. Sugita, R. Dziadziuszko, M. Tsuboi, H. Kato, P. A. Bunn, W. A. Franklin, F. R. Hirsch
Journal: Journal of Clinical Oncology (2007)

10614 Background: As for two common types of EGFR mutations, patients with exon 19 deletion mutations have longer survival than those with the L858R point mutations in exon 21 after treatment with EGFR inhibitors. We have developed a simple, polymerase chain reaction (PCR)-based method to detect exon 19 deletion mutations, and evaluated survival benefit of gefitinib treated patients with exon 19 deletion mutations versus patients without these mutations. Patients and methods: Tumor tissue was microdissected under stereoscopic microscopy from formalin-fixed paraffin-embedded sections, and DNA was extracted from tumor cells with DNeasy (Qiagen). Our method consisted of two different semi-nested PCRs with the deletion screening PCR and the common deletion specific PCR. All of the known deletions present in cell lines were detected by this method without direct sequencing. The result was validated by sequencing of exon 19. 73 non-small-cell lung cancer (NSCLC) Japanese patients treated with gefitinib were analyzed with this method. Study group consisted of 28 females (38%), 29 never smokers (40%) and 57 patients with adenocarcinoma (78%). Results: The PCR-based method detected mutations at mutant to wild type DNA copy ratio of 1/600, and in samples as small as 30 ng of purified DNA. Exon 19 deletion mutations were found in 25 (34%) patients. This method was more sensitive than conventional sequencing. The sequencing was performed in 19 patients with mutations and could not detect 3 deletions. Among 60 assessable patients 14 had overall response (23%). Objective response rates to gefitinib were observed in 7/21 patients with exon 19 deletion mutations (33%), and 7/39 patients without exon 19 deletion mutations (17%) (P = .211). Patients with exon 19 deletion mutations survived significantly longer than those without exon 19 deletion mutations (P = .017). Conclusions: The PCR-based method to detect exon 19 deletion mutations is cost effective and very sensitive, compared to previously described methods. We demonstrated survival benefit in NSCLC patients with exon 19 deletion mutations treated with gefitinib, and our PCR-based method is easily applicable for clinical use. No significant financial relationships to disclose.